Edition:
United Kingdom

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

64.13USD
15 Dec 2017
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$64.14
Open
$64.08
Day's High
$65.29
Day's Low
$63.02
Volume
860,874
Avg. Vol
458,283
52-wk High
$99.45
52-wk Low
$35.99

Select another date:

Tue, Dec 5 2017

BRIEF-Clovis Announces Priority Review Designation For Rucaparib Supplemental NDA

* CLOVIS ANNOUNCES PRIORITY REVIEW DESIGNATION FOR RUCAPARIB SUPPLEMENTAL NEW DRUG APPLICATION

BRIEF-Clovis Oncology reports Q3 adjusted shr loss of $1.24

* CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS

BRIEF-Clovis Oncology submits supplemental New Drug Application for rucaparib

* Clovis Oncology submits supplemental New Drug Application for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer

BRIEF-Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

* Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

BRIEF-Clovis Oncology Q2 loss per share $3.88

* Clovis Oncology announces second quarter 2017 operating results

BRIEF-Bristol-Myers, Clovis Oncology announce broad clinical collaboration

* Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types

BRIEF-Clovis Oncology announces underwriters' option to purchase additional shares

* Clovis Oncology announces exercise in full of underwriters' option to purchase additional shares of common stock Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology announces upsizing and pricing of public offering

* Clovis Oncology announces upsizing and pricing of public offering of common stock

BRIEF-Clovis Oncology announces proposed offering of common stock

* Clovis Oncology announces proposed offering of common stock

Clovis's ovarian cancer drug set for label expansion, shares soar

Clovis Oncology Inc said on Monday late-stage data on its already-approved ovarian cancer drug showed that the treatment could benefit four times as many patients, sending shares of the U.S. biotech soaring 50 percent.

Select another date: